← Back to Clinical Trials
Recruiting NCT06628011

NCT06628011 Digital Follow-up of Aerobic Interval Training in Outpatients With Mental Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06628011
Status Recruiting
Phase
Sponsor Norwegian University of Science and Technology
Condition Severe Mental Disorder
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-01-01
Primary Completion 2030-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Intervention group/training group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-01-01 with a primary completion date of 2030-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized-controlled trial (RCT) will investigate if digital follow-up of exercise, i.e. followup through the new citizen portal HelsaMi, coupled with an exercise app can result in exercise adherence and improved oxygen uptake in individuals with mental disorders (MD). Secondary, the project will provide information regarding effects on cardiovascular disease risk-factors, functional capacity, quality of life, satisfaction, and cost through a randomized-controlled trial (RCT) including individuals with MDs. Outcomes assessed in this project, such as maximal oxygen uptake, functional capacity, and quality of life, are strongly related to the ability to carry out activities of daily living. These outcomes are associated with benefits such as reduced sick leave, extended life expectancy, independence, and improved health status with increasing age. Economically, with the world population growing older and health care resources being stretched, there is clearly a need to apply and evaluate effective alternative methods to improve somatic health on a broader scale in a sustainable fashion, preferably utilizing existing platforms and exercise apps.

Eligibility Criteria

Inclusion Criteria: * Individuals receiving outpatient mental health treatment at the clinics of mental health at St. Olavs Hospital,. .-18-65 years old * Both men and women able to carry out exercise training. * Participants must be capable of giving informed consent and use HelsaMi. Exclusion Criteria: * Contraindications for exercise training and testing according to the ACSM specifications; life-threatening or terminal medical conditions; unable to carry out intervention or test procedures; pregnancy; mothers \<6 months post-partum. * Inpatients at an acute psychiatric ward or have any planned surgery that would interfere with the intervention.

Contact & Investigator

Central Contact

Torgeir F Fredriksen Ektvedt, PhD Candidate

✉ torgeir.fredriksen@ntnu.no

📞 +47 93082893

Frequently Asked Questions

Who can join the NCT06628011 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Severe Mental Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06628011 currently recruiting?

Yes, NCT06628011 is actively recruiting participants. Contact the research team at torgeir.fredriksen@ntnu.no for enrollment information.

Where is the NCT06628011 trial being conducted?

This trial is being conducted at Trondheim, Norway.

Who is sponsoring the NCT06628011 clinical trial?

NCT06628011 is sponsored by Norwegian University of Science and Technology. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology